Results 201 to 210 of about 243,255 (308)

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

A case of systemic toxicity after intralesional methotrexate for non-melanoma skin cancer in a patient with chronic kidney disease. [PDF]

JAAD Case Rep
Lamberg O, Powers JG, Negbenebor NA.
europepmc   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou, Sharon Edwards, Andrew Affleck   +2 more
wiley   +1 more source

L-Methionine attenuates methotrexate-induced cardiotoxicity by modulating oxidative stress, inflammation, and dyslipidemia in rats. [PDF]

Toxicol Rep
Abdel-Wahab WM, Daifalla NS, Essawy AE.
europepmc   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Strategies for Managing Toxicities With High-Dose Methotrexate in Haematological Malignancies: Lessons From Clinical Cases. [PDF]

Clin Case Rep
McLelland V, Guscott M, Wilson MR.
europepmc   +1 more source

Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug. [PDF]

, 2017
Mashayekhi, Arman, Shields, Carol L., Shields, Jerry A., Sioufi, Kareem   +3 more
core   +1 more source

Personalized AZithromycin/metronidAZole + dietary therapy in pediatric Crohn disease: Results of a pilot study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Charlotte M. Verburgt, Nikki van der Kruk, Katherine A. Dunn, PAZAZ‐study investigators, Charlotte M. Verburgt, Nikki van der Kruk, Katherine A. Dunn, Joseph P. Bielawski, Anthony R. Otley, Tim de Meij, Francisco Sylvester, Andre M. Comeau, Morgan G. I. Langille, Wouter J de Jonge, Johan E. Van Limbergen, Johan E. Van Limbergen   +15 more
wiley   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

In silico analysis of selected polyphenols as potential multitarget rheumatoid arthritis modifying agents. [PDF]

Mol Biol Rep
Sharma S, Shukla SK, Govender KK, Govender PP.   +3 more
europepmc   +1 more source